Nothing Special   »   [go: up one dir, main page]

GB2181435B - Recombinant lav/htlv virus and vaccines - Google Patents

Recombinant lav/htlv virus and vaccines

Info

Publication number
GB2181435B
GB2181435B GB8622987A GB8622987A GB2181435B GB 2181435 B GB2181435 B GB 2181435B GB 8622987 A GB8622987 A GB 8622987A GB 8622987 A GB8622987 A GB 8622987A GB 2181435 B GB2181435 B GB 2181435B
Authority
GB
United Kingdom
Prior art keywords
vaccines
htlv virus
lav
recombinant
recombinant lav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB8622987A
Other versions
GB2181435A (en
GB8622987D0 (en
Inventor
Shiu-Lok Hu
Anthony Frank Purchio
Linda Madisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of GB8622987D0 publication Critical patent/GB8622987D0/en
Publication of GB2181435A publication Critical patent/GB2181435A/en
Application granted granted Critical
Publication of GB2181435B publication Critical patent/GB2181435B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB8622987A 1985-09-25 1986-09-24 Recombinant lav/htlv virus and vaccines Expired - Fee Related GB2181435B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (3)

Publication Number Publication Date
GB8622987D0 GB8622987D0 (en) 1986-10-29
GB2181435A GB2181435A (en) 1987-04-23
GB2181435B true GB2181435B (en) 1990-01-10

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8622987A Expired - Fee Related GB2181435B (en) 1985-09-25 1986-09-24 Recombinant lav/htlv virus and vaccines

Country Status (22)

Country Link
CN (1) CN1020752C (en)
AT (1) ATA256786A (en)
CH (1) CH676247A5 (en)
DE (1) DE3690508T1 (en)
DK (1) DK455486A (en)
ES (2) ES2002490A6 (en)
FI (1) FI863848A (en)
FR (1) FR2587720A2 (en)
GB (1) GB2181435B (en)
GR (1) GR862412B (en)
HU (1) HU205780B (en)
IE (1) IE59314B1 (en)
IL (1) IL80073A (en)
IT (1) IT1195829B (en)
MY (1) MY103182A (en)
NL (1) NL8602422A (en)
NO (1) NO863803L (en)
NZ (1) NZ217645A (en)
PT (1) PT83434B (en)
SE (4) SE8604007L (en)
WO (1) WO1987002038A1 (en)
YU (1) YU46753B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860915B (en) * 1985-04-08 1986-07-11 Genetic Systems Corp Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
DE3750151T2 (en) * 1986-09-19 1994-12-01 Oncogen Use of activated T lymphocytes to prepare a pharmaceutical composition for the treatment of AIDS.
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
EP0272858A3 (en) * 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
AU608294B2 (en) * 1987-01-16 1991-03-28 Institut Pasteur Peptides having immunological properties 2-hiv-2
FR2610632B1 (en) * 1987-02-11 1990-12-21 Pasteur Institut CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
FR2620030B1 (en) * 1987-09-07 1990-03-23 Transgene Sa VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ES2059823T3 (en) * 1988-05-06 1994-11-16 Ferropas Ag METHODS AND SYSTEMS FOR PRODUCING HIV ANTIGENS.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ATE160377T1 (en) * 1989-04-18 1997-12-15 Applied Biotechnology Inc GENERATION OF HYBRID GENES AND PROTEINS BY RECOMBINATION USING VIRUSES
CA2033175C (en) * 1989-06-01 2005-01-11 Gail P. Mazzara Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (en) * 1991-05-02 1994-11-04 Pasteur Institut IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
EP1136562A3 (en) * 1991-11-08 2003-06-25 PHARMACIA & UPJOHN COMPANY Feline leukemia virus vaccines
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
CA2212682A1 (en) * 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ATE188783T1 (en) * 1995-09-06 2000-01-15 Schablonentechnik Kufstein Ag METHOD FOR MAKING A SCREEN PRINTING TEMPLATE
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173529A1 (en) * 1984-08-22 1986-03-05 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Molecular clones of the genome of HTLV-III
EP0181150B1 (en) * 1984-10-31 1993-06-09 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (en) * 1983-05-27 1992-08-15 Texas A & M Univ Sys METHOD OF GENERATING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE122005000039I1 (en) * 1984-10-18 2006-02-23 Pasteur Institut DNA fragments of the GAG gene of LAV
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DK171119B1 (en) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS virus envelope protein, expression vector carrying the envelope protein, transformants transformed with the expression vector, method of producing the virus envelope protein, method of detecting AIDS antibodies, method of determining AIDS virus, vaccine against AIDS, antibodies against the virus envelope protein and use of it to prepare a vaccine and for testing
FR2586427B1 (en) * 1985-08-20 1988-12-09 Pasteur Institut NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173529A1 (en) * 1984-08-22 1986-03-05 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Molecular clones of the genome of HTLV-III
EP0181150B1 (en) * 1984-10-31 1993-06-09 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
G.V.Quinnan"Vaccinia Vir *
Journal of Virology,Vol. *
Molecular and Cellular B *
Nature,Vol.312,pages 757 *
Nature,Vol.312,pages 760 *
Nature,Vol.320,pages 535 *
Nature,Vol.320,pages 537 *

Also Published As

Publication number Publication date
HU205780B (en) 1992-06-29
NO863803L (en) 1987-03-26
SE8604007D0 (en) 1986-09-23
SE9102976L (en) 1993-04-15
YU46753B (en) 1994-05-10
SE9102976D0 (en) 1991-10-14
SE9102975D0 (en) 1991-10-14
IE59314B1 (en) 1994-02-09
IT1195829B (en) 1988-10-27
WO1987002038A1 (en) 1987-04-09
CN1020752C (en) 1993-05-19
IE862525L (en) 1987-03-25
GR862412B (en) 1987-01-23
CN86106632A (en) 1987-05-13
GB2181435A (en) 1987-04-23
SE9102974L (en) 1993-04-15
MY103182A (en) 1993-05-29
HUT42133A (en) 1987-06-29
DK455486A (en) 1987-03-26
ATA256786A (en) 1995-05-15
IT8667730A0 (en) 1986-09-24
IL80073A (en) 1995-01-24
NO863803D0 (en) 1986-09-24
DK455486D0 (en) 1986-09-24
SE9102974D0 (en) 1991-10-14
NZ217645A (en) 1991-11-26
SE8604007L (en) 1987-03-26
PT83434B (en) 1988-07-29
SE9102975L (en) 1993-04-15
ES2002490A6 (en) 1988-08-16
PT83434A (en) 1986-10-01
GB8622987D0 (en) 1986-10-29
NL8602422A (en) 1987-04-16
DE3690508T1 (en) 1988-06-23
CH676247A5 (en) 1990-12-28
ES2006941A6 (en) 1989-05-16
FR2587720A2 (en) 1987-03-27
IL80073A0 (en) 1986-12-31
FI863848A (en) 1987-03-26
YU165486A (en) 1989-08-31
FI863848A0 (en) 1986-09-24
FR2587720B2 (en) 1995-02-10

Similar Documents

Publication Publication Date Title
GB2181435B (en) Recombinant lav/htlv virus and vaccines
IL84270A0 (en) Nor-statine and nor-cyclostatine polypeptides
DK603888D0 (en) RECOMBINANT VIRUS
DE3890874C5 (en) Recombinant viruses
NZ220653A (en) Hiv env region peptides and d-retro versions thereof
GB8821528D0 (en) Recombinant vaccinia virus
DK412787A (en) MEDICAL-SURGICAL POSE AND ITS PREPARATION
ZA881621B (en) Cyclic peptides and their preparation
IL83347A0 (en) Recombinant htlv-iii proteins and their use
EP0225777A3 (en) Insecticides and viruses
NZ224393A (en) Recombinant hiv envelope proteins and uses thereof
ZA866582B (en) Recombinant virus
IL77496A0 (en) Anti-viral preparations comprising isatine-3-thiosemicarbazones
IL81920A0 (en) Vaccines and their preparation
GB2194235B (en) Dichlorotrifluoromethyltoluenes and preparation thereof
PT86162A (en) Recombinant protein expression
ZA883878B (en) Human immunodeficiency virus gag-encoded proteins
EP0233740A3 (en) Aerocavin and aerocyanidin - antibiotics
ZA878158B (en) Nor-statine and nor-cyclostatine polypeptides
GB8509343D0 (en) Virus vaccine
GB8608991D0 (en) Virus vaccine
GR3003377T3 (en) Virus vaccine
GB8406901D0 (en) Virus vaccine
BG39532A1 (en) Thermoresistant and chemicoresistant ceramic mass
IE852241L (en) Peptides and vaccines against malaria

Legal Events

Date Code Title Description
711B Application made for correction of error (sect. 117/77)
817A Application for correction of clerical errors now open to opposition (sect. 117/1977)
711B Application made for correction of error (sect. 117/77)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19960924